The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 25, 2025

Filed:

Feb. 09, 2023
Applicant:

Estetra Srl, Liège, BE;

Inventors:

Jean-Michel Foidart, Liège, BE;

Maud Jost, Liège, BE;

Assignee:

ESTETRA SRL, Liège, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/585 (2006.01); A61K 31/565 (2006.01); A61P 15/18 (2006.01);
U.S. Cl.
CPC ...
A61K 31/585 (2013.01); A61K 31/565 (2013.01); A61P 15/18 (2018.01);
Abstract

Described are methods of providing contraception in a woman having a BMI≥30.0 kg/m, comprising: selecting a woman determined to have a BMI≥30.0 kg/m, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg. Also described are methods of contraception that achieves a Pearl Index of <5 in women having a BMI≥30.0 kg/m, comprising: selecting a woman determined to have a BMI≥30.0 kg/m, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg, wherein the method comprises daily administration of the estetrol component and drospirenone on 24 consecutive days followed by a hormone-free period of 4 consecutive days.


Find Patent Forward Citations

Loading…